Log In
Print
BCIQ
Print
Print this Print this
 

Epi proColon, Epi proColon 2.0

  Manage Alerts
Collapse Summary General Information
Company Epigenomics AG
DescriptionSecond-generation colorectal cancer test based on detection of methylated DNA of the Septin 9 gene in blood plasma by real-time PCR
Molecular Target Septin 9 (SEPT9)
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDetect colorectal cancer
Regulatory Designation U.S. - Priority Review (Detect colorectal cancer)
Partner Abbott Laboratories; BioChain Institute Inc.; Gamma-Dynacare Medical Laboratories; Polymedco Inc.; Quest Diagnostics Inc.; Sysmex Corp.; VSA Alta Complejidad S.A.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today